menu
    • menu
    [{"orgOrder":0,"company":"Helix BioPharma","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2022","type":"Termination","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase III","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"10","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"MoonLake Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Sonelokimab","moa":"Interleukin-17F | Interleukin 17A","graph1":"Dermatology","graph2":"Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"KCR","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Helix BioPharma \/ KCR","highestDevelopmentStatusID":"8","companyTruncated":"Helix BioPharma \/ KCR"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Pharm-Olam","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2015","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Pharm-Olam","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Pharm-Olam"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2019","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Theradex"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Theradex"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"L-DOS47","moa":"Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Helix BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Helix BioPharma"},{"orgOrder":0,"company":"Helix BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Vascular endothelial growth factor receptor 2 (KDR)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helix BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helix BioPharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Helix BioPharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Helix BioPharma

    Menu

    Helix BioPharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

                            Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 05, 2022

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create P...

                            Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $230.0 million

                            October 04, 2021

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : MoonLake Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

                            Details : In this next stage, the Company together with Moffit, intends to build on these early successes and provide additional preclinical support in using L-DOS47 with immunotherapies as clinical support.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            August 12, 2020

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Moffitt Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

                            Details : Topline data of the recently completed L-DOS47 dose escalation study in combination with pemetrexed and carboplatin in recurrent or metastatic non-squamous non-small cell lung cancer will be published at the ASCO 2020 Annual Conference.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : L-DOS47,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Theradex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

                            Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Pancreatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 18, 2019

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Theradex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : KCR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

                            Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Adenocarcinoma of Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 26, 2019

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : KCR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pharm-Olam

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

                            Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 16, 2015

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pharm-Olam

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helix BioPharma

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Theradex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

                            Details : L-DOS47 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 05, 2014

                            Lead Product(s) : L-DOS47

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Theradex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth